Evidence map›Paper›PMID 22202003›Full record

ReviewFrontiers in bioscience (Elite edition)2012

Molecular recognition theory and sense-antisense interaction: therapeutic applications in autoimmunity.

Matthew Thomas Hardison, James Edwin Blalock

Abstract readReview
In one paragraph

Review in Frontiers in bioscience (Elite edition), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew Thomas HardisonDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham 1918 University Blvd, Birmingham, AL 35294, USA.
James Edwin Blalock

Funding

HL-A New Pathway for Neutrophil-induced Airway InflammationR01HL077783 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2006 to 2016
$3.2M
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation inR01HL090999 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2007 to 2010
$1.5M
Therapeutics for Chronic Lung Diseases: Antagonists of PGP, Chemokines and CXCRR01HL087824 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2009 to 2010
$823k
NHLBI NIH HHS HL07783NHLBI NIH HHS HL087824NHLBI NIH HHS HL090999NHLBI NIH HHS R01 HL077783NHLBI NIH HHS R01 HL087824NHLBI NIH HHS R01 HL090999
6 · The paper itself

Abstract

Perhaps behind only the understanding of the genetic code in importance is the comprehension of protein sequence and structure in its effect on modern scientific investigation. How proteins are structured and interact dictates a considerable amount of the body's processes in maintaining homeostasis. Unfortunately, in diseases of autoimmunity, these processes are directed against the body itself and most of the current clinical responses are severely lacking. This review addresses current therapeutics involved in the treatment of various autoimmune diseases and details potential future therapeutics designed with a more targeted approach. Detailed in this manuscript is the concept of utilizing peptides possessing an inverse hydropathy to the immunogenic region of proteins to generate anti-idiotypic (anti-Id) and anti-clonotypic T cell receptor (TCR) antibodies (Abs). Theoretically, the anti-Id Abs cross react with Id Abs and negate the powerful machinery of the adaptive immune response with little to no side effects. A series of studies by a number of groups have shown this to be an exciting and intriguing concept that will likely play a role in the future treatment of autoimmune diseases.

Indexed as

Autoimmune DiseasesAutoimmunityHumans

Identifiers

PMID22202003
PMCPMC4107873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.